MGEN insider filings
Viridian Therapeutics, Inc.\DE — 12 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-01-19. Screen MGEN transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for MGEN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Viridian Therapeutics, Inc.\DE
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-01-19 | 4 | Escolar Diana — Former Chief Medical Officer | Holdings only — no transactions reported | EDGAR |
| 2021-01-19 | 4 | Rauch Lee M. | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-01-15 | 4 | Marshall William Stuart | Holdings only — no transactions reported | EDGAR |
| 2020-11-16 | 4 | Logos Global Master Fund LP — 10% owner | Purchase (P): 250,000 @ $1.10 · Purchase (P): 100,000 @ $1.16 · Purchase (P): 126,667 @ $14.84 | EDGAR |
| 2020-10-30 | 4 | Violin Jonathan — President and COO | Other (J): 50,124 · Other (J): 4,338,079 (derivative) · Other (J): 9,413 (derivative) | EDGAR |
| 2020-10-30 | 4 | Fairmount Funds Management LLC — Director Fairmount Healthcare Fund GP LLC — Director Fairmount Healthcare Fund II GP LLC — Director Fairmount Healthcare Fund L.P. — Director Fairmount Healthcare Fund II L.P. — Director | Purchase (P): 5,494 (derivative) @ $465.96 · Purchase (P): 28,843 (derivative) @ $465.96 | EDGAR |
| 2020-10-29 | 4 | Harwin Peter Evan — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2020-10-29 | 4 | Kiselak Tomas — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2020-10-29 | 4 | Fairmount Funds Management LLC — Director Fairmount Healthcare Fund GP LLC — Director Fairmount Healthcare Fund II GP LLC — Director Fairmount Healthcare Fund L.P. — Director Fairmount Healthcare Fund II L.P. — Director | Other (J): 87,891 · Other (J): 438,502 · Other (J): 16,505 (derivative) · Other (J): 82,349 (derivative) | EDGAR |
| 2020-09-17 | 4/A | Rauch Lee M. — President & CEO, Director | Grant/award (A): 900,000 (derivative) @ $0 | EDGAR |
| 2020-09-15 | 4 | Rauch Lee M. — President & CEO, Director | Grant/award (A): 900,000 (derivative) @ $0 | EDGAR |
| 2020-08-25 | 4 | Marshall William Stuart — President & CEO, Director | Holdings only — no transactions reported | EDGAR |
Recent 8-K events — Viridian Therapeutics, Inc.\DE
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-09 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-28 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-05-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-05-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MGEN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs